Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydralazine + Valproic Acid vs BSC in MDS
NCT01356875Phase 2Unknown
- Sponsor
- Osakidetza
- Start
- Sep 2011
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydralazine, valproic acid in myelodysplastic syndrome (MDS), sponsored by Osakidetza. Status: unknown.
02
Drugs
hydralazinevalproic acid
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01356875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01356875.